Arcus Biosciences/$RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
$RCUS
Sector
Primary listing
NYSE
Employees
627
Headquarters
Website
RCUS Metrics
BasicAdvanced
$1.8B
-
-$3.07
0.77
-
Price and volume
Market cap
$1.8B
Beta
0.77
52-week high
$18.42
52-week low
$6.50
Average daily volume
1.1M
Financial strength
Current ratio
4.505
Quick ratio
4.433
Long term debt to equity
21.494
Total debt to equity
23.679
Interest coverage (TTM)
-56.33%
Profitability
EBITDA (TTM)
-328
Gross margin (TTM)
-85.11%
Net profit margin (TTM)
-113.74%
Operating margin (TTM)
-129.01%
Effective tax rate (TTM)
-0.34%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-18.69%
Return on equity (TTM)
-50.34%
Valuation
Price to revenue (TTM)
6.405
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-4.907
Free cash flow yield (TTM)
-20.38%
Free cash flow per share (TTM)
-3.528
Growth
Revenue change (TTM)
6.07%
Earnings per share change (TTM)
0.92%
3-year revenue growth (CAGR)
-13.80%
3-year earnings per share growth (CAGR)
52.01%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
Bulls say / Bears say
Arcus ended Q2 2025 with $927 million in cash and marketable securities, providing funding runway through pivotal readouts for domvanalimab, casdatifan, and quemliclustat. (Nasdaq)
Interim data from the ARC-20 study showed a 46 percent confirmed overall response rate in metastatic clear cell renal cell carcinoma with casdatifan plus cabozantinib, supporting advancement into Phase 3 PEAK-1 and eVOLVE-RCC02 trials. (Arcus Press Release)
Quemliclustat received orphan drug designation from the U.S. FDA for pancreatic cancer, granting development incentives and up to seven years of market exclusivity as the registrational PRISM-1 Phase 3 trial progresses. (Arcus Press Release)
Q2 2025 revenue of $160 million was inflated by a one-time $143 million catch-up payment from Gilead’s return of the etrumadenant license, masking underlying operational performance. (Nasdaq)
Net cash used in operating activities doubled to $265 million for the six months ended June 30, 2025, signaling an accelerating cash burn that may pressure Arcus’s runway absent further non-dilutive financing. (Panabee)
Arcus paused development of etrumadenant after Gilead returned its license, reducing pipeline breadth and highlighting partner-related execution risk. (Arcus Press Release)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
RCUS News
AllArticlesVideos
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Business Wire1 week ago
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
Business Wire2 weeks ago
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $1.8B as of October 27, 2025.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of October 27, 2025.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.